Top

Published in:

01-06-2014 | Research Article

Increased expression of IL17A in human gastric cancer and its potential roles in gastric carcinogenesis

Authors: Xiaoqin Wu, Zhirong Zeng, Lixia Xu, Jun Yu, Qinghua Cao, Minhu Chen, Joseph J. Y. Sung, Pinjin Hu

Published in: Tumor Biology | Issue 6/2014

Abstract

Inflammatory cytokines modulate immune responses in the tumor microenvironment during progression. The role of interleukin (IL) 17A in cancer is currently under debate. We aim to investigate the expression of IL17A in situ tumors as well as in nontumor gastric mucosa tissues and further explore the functional significance of IL17A on gastric cancer cells in vitro. We found that compared with nontumor regions, the expression of IL17A were increased significantly in tumors of gastric cancer patients (P = 0.007). The immunoreactivity for IL17A was found only in cytoplasm of inflammatory cells as well as vascular endothelial cells but not in tumor cells. Consistently, IL17A transcription was silenced in a variety of gastric cancer cell lines. In vitro, recombinant human IL17A protein promotes cell proliferation and monolayer wound healing of both AGS and SGC7901cells, in a dose-dependent manner. Besides, IL17A inhibits H₂O₂-induced cell apoptosis. Expression of IL6 and MMP13 mRNA was increased significantly after IL17A stimulation. These data suggest that accumulation of intratumoral IL17A-producing cells may promote gastric cancer progression directly or by inducing key signal transduction pathways implicated in gastric carcinogenesis.

Available only for authorised users

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: Cancer J Clin. 2005;55(2):74–108.

Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305–15.CrossRefPubMed

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0.CrossRefPubMed

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi:10.1038/nature01322.PubMedCentralCrossRefPubMed

Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–83. doi:10.1172/jci31537.PubMedCentralCrossRefPubMed

Bornschein J, Kandulski A, Selgrad M, Malfertheiner P. From gastric inflammation to gastric cancer. Dig Dis. 2010;28(4–5):609–14. doi:10.1159/000320061.CrossRefPubMed

Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. AID. 2011. doi:10.1016/j.ccr.2008.10.011.

Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118(2):560–70. doi:10.1172/JCI32453.PubMedCentralPubMed

Michel ML, Mendes-da-Cruz D, Keller AC, Lochner M, Schneider E, Dy M, et al. Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci U S A. 2008;105(50):19845–50. doi:10.1073/pnas.0806472105.PubMedCentralCrossRefPubMed

10.

Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol. 2009;182(9):5296–305. doi:10.4049/jimmunol.0900036.CrossRefPubMed

11.

O’Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. Eur J Immunol. 2009;39(3):662–6. doi:10.1002/eji.200839120.PubMedCentralCrossRefPubMed

12.

Peng SF, Wang SJ, Chen JG, Dai XL, Shi Y, Li YZ, et al. Detection and significance of transcription factors and cytokines of Th17/Treg cells in peripheral blood in the gastric cancer patients. Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2010;32(3):185–9.

13.

Wagsater D, Lofgren S, Hugander A, Dimberg J. Expression of interleukin-17 in human colorectal cancer. Anticancer Res. 2006;26(6B):4213–6.PubMed

14.

Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008;105(40):15505–10. doi:10.1073/pnas.0710686105.PubMedCentralCrossRefPubMed

15.

Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50(5):980–9. doi:10.1016/j.jhep.2008.12.033.CrossRefPubMed

16.

Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer J Int Cancer. 2009;125(6):1372–9. doi:10.1002/ijc.24497.CrossRef

17.

Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer J Int Cancer. 2010;127(1):86–92. doi:10.1002/ijc.25027.CrossRef

18.

Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206(7):1457–64. doi:10.1084/jem.20090207.PubMedCentralCrossRefPubMed

19.

Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99(6):2114–21.CrossRefPubMed

20.

Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114(2):357–9. doi:10.1182/blood-2008-09-177360.PubMedCentralCrossRefPubMed

21.

Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of, gastric cancer. Int J Cancer. 2010;127(1):86–92.CrossRefPubMed

22.

Boyle DG, Boyle DB, Olsen V, Morgan JAT, Hyatt AD. Rapid quantitative detection of chytridiomycosis (Batrachochytrium dendrobatidis) in amphibian samples using real-time Taqman PCR assay. Dis Aqat Organ. 2004;60(2):141–8.CrossRef

23.

Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67. doi:10.1016/j.immuni.2008.03.004.PubMedCentralCrossRefPubMed

24.

Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950–7.CrossRefPubMed

25.

Caruso R, Pallone F, Monteleone G. Emerging role of IL-23/IL-17 axis in H. pylori-associated pathology. World J Gastroenterol: WJG. 2007;13(42):5547–51.PubMedCentralCrossRefPubMed

26.

Shiomi S, Toriie A, Imamura S, Konishi H, Mitsufuji S, Iwakura Y, et al. IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Nat Immunol. 2007. doi:10.1111/j.1523-5378.2008.00629.x.

27.

Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun. 2001;282(3):735–8. doi:10.1006/bbrc.2001.4618.CrossRefPubMed

28.

Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut. 2008;57(6):772–9. doi:10.1136/gut.2007.123794.CrossRefPubMed

29.

Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res: BCR. 2008;10(6):R95. doi:10.1186/bcr2195.PubMedCentralCrossRefPubMed

30.

Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer. 2011;10:150. doi:10.1186/1476-4598-10-150.PubMedCentralCrossRefPubMed

31.

Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol. 2009;70(7):547–51. doi:10.1016/j.humimm.2009.04.030.CrossRefPubMed

32.

Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620–7. doi:10.1182/blood-2002-05-1461.CrossRefPubMed

33.

Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent, angiogenesis. J Immunol. 2005;175(9):6177–61789.CrossRefPubMed

34.

Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999;59(15):3698–704.PubMed

35.

Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2007;206(7):1457–64.CrossRef

36.

He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184(5):2281–8.PubMedCentralCrossRefPubMed

37.

Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787–98. doi:10.1016/j.immuni.2009.09.014.PubMedCentralCrossRefPubMed

38.

Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008;374(3):533–7. doi:10.1016/j.bbrc.2008.07.060.CrossRefPubMed

39.

Zhou Y, Toh ML, Zrioual S, Miossec P. IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine. 2007;38(3):157–64. doi:10.1016/j.cyto.2007.06.002.CrossRefPubMed

40.

Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337–48.CrossRefPubMed

41.

Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517.CrossRefPubMed

42.

Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R, et al. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol. 2010;165(9):5332–7.CrossRef

43.

Mizuno T, Ando T, Nobata K, Tsuzuki T, Maeda O, Watanabe O, et al. Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization. World J Gastroenterol. 2005;11(40):6305–11.PubMedCentralPubMed

44.

Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22(2):83–9. doi:10.1016/j.cytogfr.2011.02.003.CrossRefPubMed

45.

Leeman MF, Curran S, Murray GI. The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol. 2002;37(3):149–66. doi:10.1080/10409230290771483.CrossRefPubMed

46.

Qiu Z, Dillen C, Hu J, Verbeke H, Struyf S, Van Damme J, et al. Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. Immunobiology. 2009;214(9–10):8358–642.

Title: Increased expression of IL17A in human gastric cancer and its potential roles in gastric carcinogenesis
Authors: Xiaoqin Wu
Zhirong Zeng
Lixia Xu
Jun Yu
Qinghua Cao
Minhu Chen
Joseph J. Y. Sung
Pinjin Hu
Publication date: 01-06-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1697-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Osteosarcoma metastasis: prospective role of ezrin

Upregulation of serum vascular endothelial growth factor and matrix metalloproteinase-3 in patients with oral squamous cell carcinoma

The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells

CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer

Aberrant BLID expression is associated with breast cancer progression

Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification

Keynote webinar | Spotlight on antibody–drug conjugates in cancer